inclisiran,evolocumab
novartis,alnylam,amgen,astellas
['novartis']
we look forward to #aha22 where dr ray will share new clinical data and findings from the 4-year long-term safety and efficacy extension study, orion-3. please join the presentation session on monday, november 7th from 3:00-4:00pm ct at main event iii 
Committed to providing US HCPs medical & scientific disease education information. See our community guidelines: https://t.co/zOLOKmRtDP